Prussian blue nanoparticles prevent RANKL ‐induced osteoclastogenesis by scavenging ROS and inactivating NF ‐ κB / MAPK signaling pathways
The FASEB Journal · 2025
DOI: 10.1096/fj.202402646r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Jiancheng Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, RANK Ligand, NF-kappa B, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Key Research and Development Program of Shaanxi, MOST | National Natural Science Foundation of China (NSFC), Natural Science Basic Research Program of Shaanxi Province.
Abstract (Originalsprache)
The accumulation of intracellular reactive oxygen species (ROS) is widely recognized to stimulate the development of osteoclasts, a crucial factor in the onset of osteoporosis. The ROS scavenging capability of Prussian blue nanoparticles (PBNPs) is exceptional, and they possess excellent biocompatibility. However, the effects of PBNPs on osteoporosis remain unknown. Present study aimed to investigate whether PBNPs could inhibit osteoclast differentiation and prevent ovariectomy (OVX)‐induced bone loss by suppressing ROS. In vitro experiments demonstrated that PBNPs attenuated osteoclastogenesis and downregulated the expression of osteoclast‐related genes. Mechanistically, PBNPs reduce cellular ROS by blocking RANKL‐induced ROS generation and increasing the expression of ROS scavenging enzymes, which in turn block the NF‐κB, ERK, JNK, and p38 pathways, thereby reducing NFATc1 signaling. According to in vivo experimental results, OVX caused a significant rise in ROS in the bone marrow, an increase in osteoclastic number on the bone surface, and substantial bone loss; however, PBNPs significantly reduced ROS and successfully protected OVX‐induced bone damages. In conclusion, this study showed for the first time that PBNPs prevented OVX‐induced bone loss and attenuate osteoclastogenesis, indicating that PBNPs may be a viable alternative therapy for the management of osteoclast‐associated bone disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Jiancheng Yang, Qinghua Tang, Siyu Li, Lei Yang, Ming Yang, Qingmei Li, Yan Feng, Mingming Pan, Yuhong Zeng
Förderung
- Key Research and Development Program of Shaanxi
- MOST | National Natural Science Foundation of China (NSFC)
- Natural Science Basic Research Program of Shaanxi Province
- Key Research and Development Projects of Shaanxi Province
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Tang, Q., Li, S., Yang, L., Yang, M., Li, Q., Feng, Y., Pan, M., & Zeng, Y. (2025). Prussian blue nanoparticles prevent RANKL ‐induced osteoclastogenesis by scavenging ROS and inactivating NF ‐ κB / MAPK signaling pathways. The FASEB Journal. https://doi.org/10.1096/fj.202402646r
Vancouver
Yang J, Tang Q, Li S, Yang L, Yang M, Li Q, et al. Prussian blue nanoparticles prevent RANKL ‐induced osteoclastogenesis by scavenging ROS and inactivating NF ‐ κB / MAPK signaling pathways. The FASEB Journal. 2025. doi:10.1096/fj.202402646r
BibTeX
@article{Yang2025,
author = {Yang, Jiancheng and Tang, Qinghua and Li, Siyu and Yang, Lei and Yang, Ming and Li, Qingmei and Feng, Yan and Pan, Mingming and Zeng, Yuhong},
title = {Prussian blue nanoparticles prevent RANKL ‐induced osteoclastogenesis by scavenging ROS and inactivating NF ‐ κB / MAPK signaling pathways},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402646r}
}
EUVIMED